Chemotherapy of trypanosomiases and leishmaniasis

Trends in Parasitology

Volumn 21, Issue 11, 2005, Pages 508-512

  Croft, Simon L ^a   Barrett, Michael P ^b   Urbina, Julio A ^c  

^a Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; ALBACONAZOLE; ALLOPURINOL; ALLOPURINOL RIBOSIDE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BENZNIDAZOLE; BISPHOSPHONIC ACID DERIVATIVE; CYSTEINE PROTEINASE INHIBITOR; DB 289; EFLORNITHINE; IMIQUIMOD; K 777; MEGLUMINE ANTIMONATE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE; POSACONAZOLE; PYRAZOLOPYRIMIDINE DERIVATIVE; RAVUCONAZOLE; SITAMAQUINE; STIBOGLUCONATE SODIUM; SURAMIN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ANTIMICROBIAL THERAPY; CHAGAS DISEASE; CLINICAL TRIAL; DRUG FORMULATION; FINANCIAL MANAGEMENT; GENE SEQUENCE; HEALTH CARE COST; HUMAN; LEISHMANIASIS; PATHOPHYSIOLOGY; REVIEW; SKIN LEISHMANIASIS; STEROL SYNTHESIS; TRYPANOSOMIASIS; VALIDATION PROCESS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CLINICAL TRIALS; DRUG THERAPY; FORECASTING; HUMANS; LEISHMANIASIS; TRYPANOSOMIASIS;

EID: 26844461073     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2005.08.026     Document Type: Review

References (37)

1. S. Sundar Drug resistance in Indian visceral leishmaniasis Trop. Med. Int. Health 6 2001 849 854
2. S. Sundar Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study Clin. Infect. Dis. 37 2003 800 804
3. Jha, T.K. et al. (2005) Paromomycin as a new cure for visceral leishmaniasis: preliminary results of a Phase III randomized controlled trial of efficacy and safety. Abstract book - Third World Congress on Leishmaniosis -April 2005, Sicily, Italy
4. J. el-On Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study J. Am. Acad. Dermatol. 27 1992 227 231
5. Ben Salah, A. et al. (2005) WR279396: an efficient nontoxic topical treatment of old world cutaneous leishmaniosis. Abstract book - Third World Congress on Leishmaniosis - April 2005, Sicily, Italy
6. S.L. Croft The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani Biochem. Pharmacol. 36 1987 2633 2636
7. S. Sundar Oral miltefosine for Indian visceral leishmaniasis N. Engl. J. Med. 347 2002 1739 1746
8. J. Soto Miltefosine for new world cutaneous leishmaniasis Clin. Infect. Dis. 38 2004 1266 1272
9. T.A. Shapiro Pharmacokinetics and metabolism of allopurinol riboside Clin. Pharmacol. Ther. 49 1991 506 514
10. C.W. Roberts Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa Mol. Biochem. Parasitol. 126 2003 129 142
11. V. Yardley In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii Antimicrob. Agents Chemother. 46 2002 929 931
12. L. Maes Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters Antimicrob. Agents Chemother. 48 2004 2056 2060
13. N.P. Sahu Synthesis of a novel quinoline derivative, 2-(2-methylquinolin- 4-ylamino)-N-phenylacetamide - a potential antileishmanial agent Bioorg. Med. Chem. 10 2002 1687 1693
14. D. Legros Treatment of human African trypanosomiasis - present situation and needs for research and development Lancet Infect. Dis. 2 2002 437 440
15. C. Burri, and R. Brun Eflornithine for the treatment of human African trypanosomiasis Parasitol. Res. 90 Suppl. 1 2003 S49 S52
16. F. Chappuis Eflornithine is safer than melarsoprol for the treatment of the second stage Trypanosoma brucei gambiense human African trypanosomiasis Clin. Infect. Dis. 41 2005 748 751
17. C. Schmid Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness Lancet 364 2004 789 790
18. R. Brun The phenomenon of treatment failures in human African trypanosomiasis Trop. Med. Int. Health 6 2001 906 914
19. J.H. Ansede O-alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection J. Med. Chem. 47 2004 4335 4338
20. S.L. Croft Pharmacological approaches to antitrypanosomal chemotherapy Mem. Inst. Oswaldo Cruz 94 1999 215 220
21. P. Poli Cytotoxic and genotoxic effects of megazol, an anti-Chagas' disease drug, assessed by different short-term tests Biochem. Pharmacol. 64 2002 1617 1627
22. M.L. Stewart Trypanocidal activity of melamine-based nitroheterocycles Antimicrob. Agents Chemother. 48 2004 1733 1738
23. A. Stich Waking up to sleeping sickness Trends Parasitol. 19 2003 195 197
24. J. Kalil, and E. Cunha-Neto Autoimmunity in Chagas disease cardiomyopathy: fulfilling the criteria at last? Parasitol. Today 12 1996 396 399
25. D.M. Engman, and J.S. Leon Pathogenesis of Chagas heart disease: role of autoimmunity Acta Trop. 81 2002 123 132
26. R.L. Tarleton Parasite persistence in the aetiology of Chagas disease Int. J. Parasitol. 31 2001 550 554
27. S. Sosa Estani Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease Am. J. Trop. Med. Hyg. 59 1998 526 529
28. J.A. Urbina, and R. Docampo Specific chemotherapy of Chagas disease: controversies and advances Trends Parasitol. 19 2003 495 501
29. J.J. Cazzulo Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease Curr. Top. Med. Chem. 2 2002 1261 1271
30. L.R. Garzoni Antiparasitic activity of risedronate in a murine model of acute Chagas' disease Int. J. Antimicrob. Agents 23 2004 286 290
31. A. Schmidt, and R.L. Krauth-Siegel Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development Curr. Top. Med. Chem. 2 2002 1239 1259
32. N.M. El-Sayed Comparative genomics of trypanosomatid parasitic protozoa Science 309 2005 404 409
33. P. Preziosi Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? Nat. Rev. Drug Discov. 3 2004 521 526
34. B. Booth, and R. Zemmel Prospects for productivity Nat. Rev. Drug Discov. 3 2004 451 456
35. P. Trouiller Drug development for neglected diseases: a deficient market and a public-health policy failure Lancet 359 2002 2188 2194
36. P. Trouiller Drugs for neglected diseases: a failure of the market and a public health failure? Trop. Med. Int. Health 6 2001 945 951
37. C.M. Morel Health innovation networks to help developing countries address neglected diseases Science 309 2005 401 404